Tag

Anne Wojcicki

All articles tagged with #anne wojcicki

23andMe sale to founder-led nonprofit approved amid legal and regulatory challenges
business8 months ago

23andMe sale to founder-led nonprofit approved amid legal and regulatory challenges

Anne Wojcicki's nonprofit TTAM Research Institute has been approved to buy back 23andMe for $305 million after the company's bankruptcy, marking a significant turnaround. The deal includes key assets like the DNA testing service and research operations, amid ongoing privacy concerns and legal challenges related to customer data. Wojcicki aims to continue the company's mission to democratize access to genetic information, with commitments to privacy and transparency.

Anne Wojcicki's Nonprofit Wins Bid to Reclaim 23andMe
business8 months ago

Anne Wojcicki's Nonprofit Wins Bid to Reclaim 23andMe

Anne Wojcicki, former CEO of 23andMe, regained control of the genetic testing company by bidding $305 million at auction, outbidding Regeneron Pharmaceuticals, after the company filed for bankruptcy due to declining demand and a data breach. The sale has sparked legal challenges from multiple states over privacy concerns, with a court hearing scheduled to determine the company's future.

Anne Wojcicki acquires 23andMe in strategic buyback
business8 months ago

Anne Wojcicki acquires 23andMe in strategic buyback

A nonprofit controlled by Anne Wojcicki has won the bid to buy 23andMe out of bankruptcy, potentially allowing Wojcicki to return as CEO. The deal, worth $305 million, raises privacy concerns over genetic data, with legal challenges from states over the sale of genetic information without explicit consent. The sale aims to continue 23andMe's mission of accessible genetic understanding while addressing privacy issues.

23andMe Slashes Workforce and Ends Therapeutics Amid Cost-Cutting Measures
business1 year ago

23andMe Slashes Workforce and Ends Therapeutics Amid Cost-Cutting Measures

Genetic testing company 23andMe is cutting 40% of its workforce, amounting to 200 employees, and halting all therapy program developments as part of a restructuring effort. CEO Anne Wojcicki stated the move aims to focus on the company's core consumer business and research partnerships. The company is also exploring strategic alternatives for its therapies, such as licensing agreements and asset sales. Wojcicki's attempt to take the company private has faced challenges, including the resignation of independent directors in September. The restructuring is expected to save over $35 million annually.